PDF herunterladen
Pharmacopsychiatry
DOI: 10.1055/a-2479-9430
Original Paper

Exposure to Psychotropic Drugs and Colorectal Cancer Risk in Patients with Affective Disorder: A Nested Case-Control Study

Tien-Wei Hsu
1   Department of Psychiatry, E-Da Dachang Hospital, I-Shou University, Kaohsiung, Taiwan
2   Department of Psychiatry, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan
,
Shih-Jen Tsai
3   Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan
4   Department of Psychiatry, School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
,
Tzeng-Ji Chen
5   Department of Family Medicine, Taipei Veterans General Hospital, Hsinchu Branch, Hsinchu, Taiwan
6   Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei, Taiwan
,
Mu-Hong Chen    #
3   Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan
4   Department of Psychiatry, School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
,
Chih-Sung Liang    #
7   Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
8   Department of Psychiatry, National Defense Medical Center, Taipei, Taiwan
› Institutsangaben Funding Hsinchu Science Park Bureau, Ministry of Science and Technology, Taiwan — http://dx.doi.org/10.13039/501100021806; 107–2314-B-075-063-MY3, 108-2314-B-075 -037 Yen Tjing Ling Industrial Research Institute, National Taiwan University — http://dx.doi.org/10.13039/501100006732; CI-109-21, CI-109-22, CI-110-30 Taipei Veterans General Hospital — http://dx.doi.org/10.13039/501100011912; V106B-020, V107B-010, V107C-181, V108B-012, V110C-
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Background This study aimed to assess the association between the risk of colorectal cancer (CRC) and exposure to mood stabilizers, antidepressants, and antipsychotics in patients with affective disorders.

Methods This nested case-control study used data from the National Health Insurance Database of Taiwan collected between 2001 and 2011. All participants in this study had affective disorders. Then, 1209 patients with CRC and 1:10 matched controls were identified based on their demographic and clinical characteristics. A logistic regression model adjusted for demographic and clinical characteristics was used to determine the risk of developing CRC after exposure to psychotropic drugs.

Results Among patients with affective disorders, exposure to mood stabilizers (reported as odds ratio; 95% confidence interval; 0.75; 0.57–0.98), antidepressants (0.83; 0.70–0.97), second-generation antipsychotics (0.67; 0.52–0.86), and first-generation antipsychotics (0.65; 0.52–0.81) were associated with a reduced risk of CRC compared to patients who were not exposed. When considering specific drugs, carbamazepine (0.34; 0.12–0.95), valproic acid (0.66; 0.46–0.95), gabapentin (0.44; 0.20–0.99), fluoxetine (0.82; 0.68–0.99), paroxetine (0.63; 0.45–0.87), and venlafaxine (0.72; 0.55–0.95) were associated with a lower risk of CRC.

Conclusion Exposure to psychotropic drugs in patients with affective disorders is associated with a lower risk of CRC compared to those who were not exposed. Although the causal relationship between psychotropic drug exposure and reduced risk of CRC could not be inferred directly, these findings may help clinicians and patients in clinical decision-making.

Keywords

colorectal cancer - affective disorder - mood stabilizer - antidepressant - antipsychotic

# Mu-Hung Chen and Chih-Sung Liang are co-corresponding authors of this paper and have contributed equally in this capacity.


Supplementary Material



Publikationsverlauf

Eingereicht: 06. August 2024
Eingereicht: 19. Oktober 2024

Angenommen: 12. November 2024

Artikel online veröffentlicht:
17. Dezember 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Sawicki T, Ruszkowska M, Danielewicz A. et al. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers (Basel) 2021; 13
    CrossrefPubMedSuche in Google Scholar
  • 2 Fraile-Martinez O, Alvarez-Mon MA, Garcia-Montero C. et al. Understanding the basis of major depressive disorder in oncological patients: Biological links, clinical management, challenges, and lifestyle medicine. Front Oncol 2022; 12: 956923
    CrossrefPubMedSuche in Google Scholar
  • 3 Anmella G, Fico G, Lotfaliany M. et al. Risk of cancer in bipolar disorder and the potential role of lithium: International collaborative systematic review and meta-analyses. Neurosci Biobehav Rev 2021; 126: 529-541
    CrossrefPubMedSuche in Google Scholar
  • 4 Jia Y, Li F, Liu YF. et al. Depression and cancer risk: A systematic review and meta-analysis. Public Health 2017; 149: 138-148
    CrossrefPubMedSuche in Google Scholar
  • 5 Chubak J, Boudreau DM, Rulyak SJ. et al. Colorectal cancer risk in relation to antidepressant medication use. Int J Cancer 2011; 128: 227-232
    CrossrefPubMedSuche in Google Scholar
  • 6 Coogan PF, Strom BL, Rosenberg L. Antidepressant use and colorectal cancer risk. Pharmacoepidemiol Drug Saf 2009; 18: 1111-1114
    CrossrefPubMedSuche in Google Scholar
  • 7 Xu W, Tamim H, Shapiro S. et al. Use of antidepressants and risk of colorectal cancer: A nested case-control study. Lancet Oncol 2006; 7: 301-308
    CrossrefPubMedSuche in Google Scholar
  • 8 Takada M, Fujimoto M, Motomura H. et al. Inverse association between sodium channel-blocking antiepileptic drug use and cancer: Data mining of spontaneous reporting and claims databases. Int J Med Sci 2016; 13: 48-59
    CrossrefPubMedSuche in Google Scholar
  • 9 Chen VC, Hsieh YH, Lin TC. et al. New use for old drugs: The protective effect of risperidone on colorectal cancer. Cancers (Basel) 2020; 12
    CrossrefPubMedSuche in Google Scholar
  • 10 Dalton SO, Johansen C, Poulsen AH. et al. Cancer risk among users of neuroleptic medication: A population-based cohort study. Br J Cancer 2006; 95: 934-939
    CrossrefPubMedSuche in Google Scholar
  • 11 Gil-Ad I, Zolokov A, Lomnitski L. et al. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice. Int J Oncol 2008; 33: 277-286
    PubMedSuche in Google Scholar
  • 12 Akbarzadeh L, Moini Zanjani T, Sabetkasaei M. Comparison of anticancer effects of carbamazepine and valproic acid. Iran Red Crescent Med J 2016; 18: e37230
    CrossrefPubMedSuche in Google Scholar
  • 13 Haukka J, Sankila R, Klaukka T. et al. Incidence of cancer and antidepressant medication: Record linkage study. Int J Cancer 2010; 126: 285-296
    CrossrefPubMedSuche in Google Scholar
  • 14 Clemente AS, Diniz BS, Nicolato R. et al. Bipolar disorder prevalence: A systematic review and meta-analysis of the literature. Braz J Psychiatry 2015; 37: 155-161
    CrossrefPubMedSuche in Google Scholar
  • 15 Hasin DS, Sarvet AL, Meyers JL. et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry 2018; 75: 336-346
    CrossrefPubMedSuche in Google Scholar
  • 16 Hammer-Helmich L, Haro JM, Jonsson B. et al. Functional impairment in patients with major depressive disorder: The 2-year PERFORM study. Neuropsychiatr Dis Treat 2018; 14: 239-249
    CrossrefPubMedSuche in Google Scholar
  • 17 Peters AT, West AE, Eisner L. et al. The burden of repeated mood episodes in bipolar I disorder: Results from the National Epidemiological Survey on Alcohol and Related Conditions. J Nerv Ment Dis 2016; 204: 87-94
    CrossrefPubMedSuche in Google Scholar
  • 18 Dickerson F, Stallings CR, Origoni AE. et al. Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999-2011. Psychiatr Serv 2013; 64: 44-50
    CrossrefPubMedSuche in Google Scholar
  • 19 Liu YK, Ling S, Lui LMW. et al. Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis. J Affect Disord 2022; 300: 449-461
    CrossrefPubMedSuche in Google Scholar
  • 20 Luppino FS, de Wit LM, Bouvy PF. et al. Overweight, obesity, and depression: A systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67: 220-229
    CrossrefPubMedSuche in Google Scholar
  • 21 Mathew AR, Hogarth L, Leventhal AM. et al. Cigarette smoking and depression comorbidity: Systematic review and proposed theoretical model. Addiction 2017; 112: 401-412
    CrossrefPubMedSuche in Google Scholar
  • 22 Puddephatt JA, Irizar P, Jones A. et al. Associations of common mental disorder with alcohol use in the adult general population: A systematic review and meta-analysis. Addiction 2022; 117: 1543-1572
    CrossrefPubMedSuche in Google Scholar
  • 23 Huang JS, Yang FC, Chien WC. et al. Risk of substance use disorder and its associations with comorbidities and psychotropic agents in patients with autism. JAMA Pediatr 2021; 175: e205371
    CrossrefPubMedSuche in Google Scholar
  • 24 Liang CS, Bai YM, Hsu JW. et al. The risk of sexually transmitted infections following first-episode schizophrenia among adolescents and young adults: A cohort study of 220 545 subjects. Schizophr Bull 2020; 46: 795-803
    CrossrefPubMedSuche in Google Scholar
  • 25 Hsu TW, Liang CS, Tsai SJ. et al. Risk of major psychiatric disorders among children and adolescents surviving malignancies: A nationwide longitudinal study. J Clin Oncol 2023; 41: 2054-2066
    CrossrefPubMedSuche in Google Scholar
  • 26 Chen MH, Hsu JW, Huang KL. et al. Risk and coaggregation of major psychiatric disorders among first-degree relatives of patients with bipolar disorder: A nationwide population-based study. Psychol Med 2019; 49: 2397-2404
    CrossrefPubMedSuche in Google Scholar
  • 27 Chen MH, Lan WH, Hsu JW. et al. Risk of developing type 2 diabetes in adolescents and young adults with autism spectrum disorder: A nationwide longitudinal study. Diabetes care 2016; 39: 788-793
    CrossrefPubMedSuche in Google Scholar
  • 28 Cheng CM, Chang WH, Chen MH. et al. Co-aggregation of major psychiatric disorders in individuals with first-degree relatives with schizophrenia: A nationwide population-based study. Molecular psychiatry 2018; 23: 1756-1763
    CrossrefPubMedSuche in Google Scholar
  • 29 Huang MH, Cheng CM, Tsai SJ. et al. Familial coaggregation of major psychiatric disorders among first-degree relatives of patients with obsessive-compulsive disorder: A nationwide study. Psychol Med 2020; 1-8
    CrossrefPubMedSuche in Google Scholar
  • 30 Liu CY, Hung YT, Chuang YL. et al. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Management (Chin) 2006; 4: 1-22
    PubMedSuche in Google Scholar
  • 31 Charlson ME, Pompei P, Ales KL. et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383
    CrossrefPubMedSuche in Google Scholar
  • 32 Hsu TW, Bai YM, Tsai SJ. et al. Risk of retinal disease in patients with bipolar disorder: A nationwide cohort study. Psychiatry Clin Neurosci 2022; 76: 106-113
    CrossrefPubMedSuche in Google Scholar
  • 33 Hsu TW, Chen MH, Chu CS. et al. Attention deficit hyperactivity disorder and risk of migraine: A nationwide longitudinal study. Headache 2022; 62: 634-641
    CrossrefPubMedSuche in Google Scholar
  • 34 Kuo HY, Liang CS, Tsai SJ. et al. Dose-dependent proton pump inhibitor exposure and risk of type 2 diabetes: A nationwide nested case-control study. Int J Environ Res Public Health 2022; 19
    CrossrefPubMedSuche in Google Scholar
  • 35 Brackenbury WJ. Voltage-gated sodium channels and metastatic disease. Channels (Austin) 2012; 6: 352-361
    CrossrefPubMedSuche in Google Scholar
  • 36 Wheler JJ, Janku F, Falchook GS. et al. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol 2014; 73: 495-501
    CrossrefPubMedSuche in Google Scholar
  • 37 Yang M, Kozminski DJ, Wold LA. et al. Therapeutic potential for phenytoin: Targeting Na(v)1.5 sodium channels to reduce migration and invasion in metastatic breast cancer. Breast Cancer Res Treat 2012; 134: 603-615
    CrossrefPubMedSuche in Google Scholar
  • 38 Kim HJ, Bae SC. Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 2011; 3: 166-179
    PubMedSuche in Google Scholar
  • 39 Ahmadi R, Sepehri B, Irani M. et al. In-silico optimization of frizzled-8 receptor inhibition activity of carbamazepine: Design new anti-cancer agent. Comb Chem High Throughput Screen 2023; 26: 696-705
    CrossrefPubMedSuche in Google Scholar
  • 40 Beutler AS, Li S, Nicol R. et al. Carbamazepine is an inhibitor of histone deacetylases. Life Sci 2005; 76: 3107-3115
    CrossrefPubMedSuche in Google Scholar
  • 41 Bilen MA, Fu S, Falchook GS. et al. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemother Pharmacol 2015; 75: 869-874
    CrossrefPubMedSuche in Google Scholar
  • 42 Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E. et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 2006; 6: 2
    CrossrefPubMedSuche in Google Scholar
  • 43 Sigler RE, Gough AW, de la Iglesia FA. Pancreatic acinar cell neoplasia in male Wistar rats following 2 years of gabapentin exposure. Toxicology 1995; 98: 73-82
    CrossrefPubMedSuche in Google Scholar
  • 44 da Cunha LP, Rey MEC, Jorge DCR. et al. High dose gabapentin does not alter tumor growth in mice but reduces arginase activity and increases superoxide dismutase, IL-6 and MCP-1 levels in Ehrlich ascites. BMC Res Notes 2019; 12: 59
    CrossrefPubMedSuche in Google Scholar
  • 45 Zhang JL, Yang JP, Zhang JR. et al. Gabapentin reduces allodynia and hyperalgesia in painful diabetic neuropathy rats by decreasing expression level of Nav1.7 and p-ERK1/2 in DRG neurons. Brain Res 2013; 1493: 13-18
    CrossrefPubMedSuche in Google Scholar
  • 46 Bugan I, Karagoz Z, Altun S. et al. Gabapentin, an analgesic used against cancer-associated neuropathic pain: Effects on prostate cancer progression in an in vivo rat model. Basic Clin Pharmacol Toxicol 2016; 118: 200-207
    CrossrefPubMedSuche in Google Scholar
  • 47 Huang RY, Hsieh KP, Huang WW. et al. Use of lithium and cancer risk in patients with bipolar disorder: Population-based cohort study. Br J Psychiatry 2016; 209: 393-399
    CrossrefPubMedSuche in Google Scholar
  • 48 Suganthi M, Sangeetha G, Gayathri G. et al. Biphasic dose-dependent effect of lithium chloride on survival of human hormone-dependent breast cancer cells (MCF-7). Biol Trace Elem Res 2012; 150: 477-486
    CrossrefPubMedSuche in Google Scholar
  • 49 Boursi B, Lurie I, Mamtani R. et al. Anti-depressant therapy and cancer risk: A nested case-control study. Eur Neuropsychopharmacol 2015; 25: 1147-1157
    CrossrefPubMedSuche in Google Scholar
  • 50 Kuwahara J, Yamada T, Egashira N. et al. Comparison of the anti-tumor effects of selective serotonin reuptake inhibitors as well as serotonin and norepinephrine reuptake inhibitors in human hepatocellular carcinoma cells. Biol Pharm Bull 2015; 38: 1410-1414
    CrossrefPubMedSuche in Google Scholar
  • 51 Jang WJ, Jung SK, Vo TTL. et al. Anticancer activity of paroxetine in human colon cancer cells: Involvement of MET and ERBB3. J Cell Mol Med 2019; 23: 1106-1115
    CrossrefPubMedSuche in Google Scholar
  • 52 Kannen V, Hintzsche H, Zanette DL. et al. Antiproliferative effects of fluoxetine on colon cancer cells and in a colonic carcinogen mouse model. PLoS One 2012; 7: e50043
    CrossrefPubMedSuche in Google Scholar
  • 53 Kannen V, Marini T, Turatti A. et al. Fluoxetine induces preventive and complex effects against colon cancer development in epithelial and stromal areas in rats. Toxicol Lett 2011; 204: 134-140
    CrossrefPubMedSuche in Google Scholar
  • 54 Durand JP, Alexandre J, Guillevin L. et al. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs 2005; 16: 587-591
    CrossrefPubMedSuche in Google Scholar
  • 55 Rabin EE, Kim M, Mozny A. et al. A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer. Brain Behav Immun Health 2022; 21: 100449
    CrossrefPubMedSuche in Google Scholar
  • 56 Fond G, Macgregor A, Attal J. et al. Antipsychotic drugs: Pro-cancer or anti-cancer? A systematic review. Med Hypotheses 2012; 79: 38-42
    CrossrefPubMedSuche in Google Scholar
  • 57 Badran A, Tul-Wahab A, Zafar H. et al. Antipsychotics drug aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro. PLoS One 2020; 15: e0235676
    CrossrefPubMedSuche in Google Scholar
  • 58 Papadopoulos F, Isihou R, Alexiou GA. et al. Haloperidol induced cell cycle arrest and apoptosis in glioblastoma cells. Biomedicines 2020; 8
    CrossrefPubMedSuche in Google Scholar
  • 59 Dilly SJ, Clark AJ, Marsh A. et al. A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment. Cancer Lett 2017; 393: 16-21
    CrossrefPubMedSuche in Google Scholar
  • 60 Dilly SJ, Morris GS, Taylor PC. et al. Clinical pharmacokinetics of a lipid-based formulation of risperidone, VAL401: Analysis of a single dose in an open-label trial of late-stage cancer patients. Eur J Drug Metab Pharmacokinet 2019; 44: 557-565
    CrossrefPubMedSuche in Google Scholar